Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > The number of Board Members

<< Previous

Bullboard Posts

Next >>

Comment by YegJeeberon Apr 09, 2023 4:31pm

142 Views

Post# 35385977

RE:RE:RE:The number of Board Members

I'm thinking the initial share price boost will come with the announcement that one or two phase 3 trials have been approved - the primary operational goal of biotechs. If that can get the price to $10 a share or better, then the business development side of a significant buyout will be much easier to promote.

In my opinion, the ball is not I. ONCY's court nor is it in big pharma's - it's in the FDA's to grant the P3.

<< Previous

Bullboard Posts

Next >>

Boeing workers end strike, return to work